Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

889

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

889 results for “fatty liver”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease

ClinicalTrials.gov study NCT00633282. IPD Sharing: Not stated. Countries: 1. Publications: 11.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Kidney Affection in Non Alcaholic Fatty Liver Diseases

ClinicalTrials.gov study NCT04273230. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

ClinicalTrials.gov study NCT03350165. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease

ClinicalTrials.gov study NCT02690792. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

ClinicalTrials.gov study NCT03060538. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine

ClinicalTrials.gov study NCT03300661. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

The Influence of SARS-CoV-2 Lifestyle Changes on Non-alcoholic Fatty Liver Disease Evolution

ClinicalTrials.gov study NCT05416970. IPD Sharing: YES. Countries: 1. Publications: 3.

controlledIPD-YESFeb 2026View details →
dryad32/100

Data from: Widespread dysregulation of long non-coding genes associated with fatty acid metabolism, cell division, and immune response gene networks in xenobiotic-exposed rat liver

Open the record for dataset details and reuse information.

publicFeb 2020View details →
dryad28/100

Data from: Dietary macronutrients modulate the fatty acyl composition of rat liver mitochondrial cardiolipins

The interaction of dietary fats and carbohydrates on liver mitochondria were examined in male FBNF1 rats fed 20 different low-fat, isocaloric diets. Animal growth rates and mitochondrial respiratory parameters were essentially unaffected, but mass spectrometry-based, mitochondrial lipidomics profiling revealed increased levels of cardiolipins (CLs), a family of phospholipids essential for mitochondrial structure and function, in rats fed saturated or trans fat-based diets with a high glycemic index. These mitochondria showed elevated monolysocardiolipins (a CL precursor/product of CL degradation), elevated ratio of trans PC (18:1/18:1) to cis PC (18:1/18:1) (a marker of thiyl radical stress), and decreased ubiquinone Q9 -- the latter two of which imply a low-grade mitochondrial redox abnormality. Extended analysis demonstrated: (i) dietary fats and, to a lesser extent, carbohydrates induce changes in the relative abundance of specific CL species; (ii) Fatty acid (FA) incorporation into mature CLs undergoes both positive (>400-fold) and negative (2.5-fold) regulation; and, (iii) dietary lipid abundance and incorporation of FAs into both the CL pool and specific mature tetra-acyl CLs are inversely related, suggesting previously unobserved compensatory regulation. This study reveals previously unobserved complexity/regulation of the central lipid in mitochondrial metabolism.

opencc-zeroDec 2012View details →
zenodo28/100

EFFECTIVENESS OF COMPLEX TREATMENT OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN PSORIATIC ARTHRITIS

Open the record for dataset details and reuse information.

opencc-by-4.0Nov 2023View details →
zenodo28/100

Step Change - CSI 2 – Non-Alcoholic Fatty Liver Disease in the UK – Infographic

Open the record for dataset details and reuse information.

opencc-by-4.0Apr 2024View details →
zenodo28/100

Rodent Model of Non-alcoholic Fatty Liver Disease: A Systematic Review

Open the record for dataset details and reuse information.

opencc-by-4.0Apr 2024View details →
dryad28/100

Data from: Effects of 4-Hydroxy-2,3,3',4',5-pentachlorobiphenyl (4-OH-CB107) on liver transcriptome in rats: implication in the disruption of circadian rhythm and fatty acid metabolism

Polychlorinated biphenyls (PCBs) and their hydroxylated metabolites (OH-PCBs) have been detected in tissues of both wild animals and humans. Several previous studies have suggested adverse effects of OH-PCBs on the endocrine and nervous systems in mammals. However, there have been no studies on transcriptome analysis of the effects of OH-PCBs, and thus, the whole picture and mechanisms underlying the adverse effects induced by OH-PCBs are still poorly understood. We therefore investigated the mRNA expression profile in the liver of adult male Wistar rats treated with 4-hydroxy-2,3,3',4',5-pentachlorobiphenyl (4-OH-CB107) to explore the genes responsive to OH-PCBs and to understand the potential effects of the chemical. Next-generation RNA sequencing analysis revealed changes in the expression of genes involved in the circadian rhythm and fatty acid metabolism, such as nuclear receptor subfamily 1, group D, member 1 (Nr1d1), aryl hydrocarbon receptor nuclear translocator-like protein 1 (Arntl), cryptochrome circadian clock 1 (Cry1), and enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase (Ehhadh), in 4-OH-CB107-treated rats. In addition, biochemical analysis of the plasma revealed a dose-dependent increase in the leucine aminopeptidase (LAP), indicating the onset of liver damage. These results suggest that OH-PCB exposure may induce liver injury as well as disrupt the circadian rhythm and peroxisome proliferator-activated receptor (PPAR)-related fatty acid metabolism.

opencc-zeroDec 2017View details →
dryad28/100

Nonalcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes

<p><span>Objectives: Nonalcoholic fatty liver disease (NAFLD) is associated with incident type 2 diabetes; however, the extent to which NAFLD may confer its risk remains uncertain, especially in Europeans. Emerging evidence suggests that sleep behaviors are linked to NAFLD and diabetes. We aimed to measure whether sleep behaviors modified the association between NAFLD and incident type 2 diabetes.</span></p> <p><span>Methods: This prospective cohort study included 362,834 participants without type 2 diabetes at baseline in UK Biobank data. Five sleep behaviors, including sleep duration, insomnia, snoring, chronotype, and daytime sleepiness, were collected from the questionnaire. Liver steatosis was based on the fatty liver index.</span></p> <p><span>Results: During a median follow-up of 10.9 years, we documented 7,394 patients with incident type 2 diabetes. NAFLD was significantly associated with increased diabetes risk. Sleeping 7-8 h/day, no insomnia, no self-reported snoring and no frequent daytime sleepiness were independently associated with incident type 2 diabetes, with a 19%, 19%, 13%, and 29% lower risk, respectively. 33.8% and 33.5% of type 2 diabetes events in this cohort could be attributed to NAFLD and poor sleep pattern, respectively. We further found significant interaction between NAFLD and sleep duration and insomnia (<i>P</i> for interaction = 0.027 and 0.025, respectively). Compared those with NAFLD and abnormal sleep duration (≤6 h or ≥9 h) or insomnia, participants with non-NAFLD and normal sleep duration or non-insomnia had 57% (RR 0.43, 95% CI 0.40, 0.47) or 55% (RR 0.45, 95% CI 0.41, 0.50) lower risk of incident diabetes. These associations were independent of age, sex, ethnicity, education, family history, economic status, lifestyles, hemoglobin A1c, systolic blood pressure, total cholesterol, and associated medications.</span></p> <p><span>Conclusion: Both NAFLD and some sleep behaviors were risk factors for type 2 diabetes. Insomnia and sleep duration modified the association between NAFLD and type 2 diabetes.</span></p>

opencc-zeroSep 2021View details →
ClinicalTrials.gov28/100

Vitamin D Replacement in Nonalcoholic Fatty Liver Disease

ClinicalTrials.gov study NCT03084328. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

ClinicalTrials.gov study NCT06024408. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

ClinicalTrials.gov study NCT06007651. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut University Hospitals

ClinicalTrials.gov study NCT04482153. IPD Sharing: Not stated. Countries: 0. Publications: 11.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV

ClinicalTrials.gov study NCT06589167. IPD Sharing: NO. Countries: 0. Publications: 13.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt

ClinicalTrials.gov study NCT04861012. IPD Sharing: UNDECIDED. Countries: 0. Publications: 23.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record